U.S. markets closed
  • S&P Futures

    4,157.75
    -25.75 (-0.62%)
     
  • Dow Futures

    34,566.00
    -102.00 (-0.29%)
     
  • Nasdaq Futures

    13,198.25
    -158.50 (-1.19%)
     
  • Russell 2000 Futures

    2,184.70
    -24.90 (-1.13%)
     
  • Crude Oil

    64.51
    -0.41 (-0.63%)
     
  • Gold

    1,835.10
    -2.50 (-0.14%)
     
  • Silver

    27.34
    -0.15 (-0.55%)
     
  • EUR/USD

    1.2136
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.6020
    +0.0250 (+1.59%)
     
  • Vix

    19.66
    +2.97 (+17.80%)
     
  • GBP/USD

    1.4123
    +0.0001 (+0.01%)
     
  • USD/JPY

    108.9500
    +0.1090 (+0.10%)
     
  • BTC-USD

    55,442.23
    -3,271.23 (-5.57%)
     
  • CMC Crypto 200

    1,454.96
    -106.33 (-6.81%)
     
  • FTSE 100

    7,123.68
    -6.03 (-0.08%)
     
  • Nikkei 225

    28,839.43
    -678.91 (-2.30%)
     

Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference

  • Oops!
    Something went wrong.
    Please try again later.
Vor Biopharma
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Cowen 41st Annual Health Care Conference, which will take place virtually on March 1-4, 2021. Robert Ang, MBBS, MBA, Vor’s President and Chief Executive Officer, and Nathan Jorgensen, PhD, Chief Financial Officer, are scheduled to present on Thursday, March 4, 2021, at 1:30 p.m. E.T.

About Vor Biopharma

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.

Contacts:

Investor:
Constantine Davides, CFA
Westwicke
+1 339-970-2846
constantine.davides@westwicke.com

Media:
Mary Carmichael
Ten Bridge Communications
+1 617-413-3543
mary@tenbridgecommunications.com